Immune cells and cells activated by the inflammatory cytokine interferon express variant proteasomes called immunoproteasomes that are characterized by unique catalytic subunits. Seifert et al. (2010) now show in mouse models of inflammatory disease that immunoproteasomes help prevent the accumulation of harmful protein aggregates.
The proteasome recognizes and degrades proteins substrates modified with polyubiquitin chains, and small protein fragments generated by the proteasome can be used by major histocompatibility complex (MHC) class I molecules for the display of antigens to the immune system. However, this simple picture is complicated by the presence of genes at the MHC locus that encode two variant catalytic subunits of the proteasome, lmp2/b1i and lmp7/b5i. These two subunits (along with a third one, MECL1/b2i) are abundant in cells of the immune system and are expressed in other cell types after exposure to the cytokine interferon g. Consequently, immune cells expressing these variant catalytic subunits have specialized proteasomes, called immunoproteasomes. The question is ''why''? In this issue, Seifert et al. (2010) reveal a surprising role for immunoproteasomesthe prevention of protein aggregate formation during inflammation.
Prior work has indicated that immunoproteasomes promote the generation of relevant peptides for presentation by MHC class I molecules, and in vitro experiments demonstrate that immunoproteasomes (containing lmp2 and lmp7) to a certain extent produce different peptides than standard proteasomes. However, the phenotypes of mice lacking lmp2 or lmp7 are very subtle, suggesting that immunoproteasomes are likely to have a minor role at most in antigen processing (Kloetzel and Ossendorp, 2004 Prior work has also shown that immunoproteasomes are more active than standard proteasomes. The proteasome is in fact a slow protease (Yewdell, 2001; Yewdell et al., 2003) , and its activity becomes rate limiting when the amount of substrate presented for degradation exceeds that which occurs under steady-state conditions. The findings of Seifert et al. now suggest that the enhanced activity of the immunoproteasomes (relative to standard proteasomes) prevents the accumulation of degradation substrates that would otherwise aggregate during inflammation ( Figure 1 ).
An increase protein synthesis results from activation of the mTOR pathway downstream of stimulation by the inflammatory cytokine interferon and numerous other stimuli, including ionizing radiation and insulin (Reits et al., 2006; Ma and Blenis, 2009) . A large fraction of newly generated proteins are defective in folding, translation, or assembly and thus need to be destroyed in order to prevent the formation of potentially harmful aggregates. These products are collectively called defective ribosomal products (DRiPs). Seifert and colleagues now show that immunoproteasomes are essential for the degradation of DRiPs resulting from mTOR-induced translation after interferon g exposure.
At least two mechanisms-protein production and protein damage-contribute to the generation of an interferon g-induced protein pool that requires degradation by the immunoproteasome. Similar to ionizing radiation (Reits et al., 2006) , interferon g produces radicals, presumably by activating the inducible nitric oxide synthase (iNOS) system. The resulting radicals lead to oxidative-protein damage. The authors show that newly synthesized proteins are very sensitive to oxygen radicals (although existing proteins should also be modified given that radicals are not selective). The authors show that the damaged proteins further enhance the pool of DRiPs that cannot be fully handled by the normal proteasome but instead require immunoproteasomes for efficient destruction.
In the ''substrate recognition-ubiquitination-degradation'' reaction cascade ubiquitin ligation should be close to limiting. Indeed, the E2/E3 ligase system determines substrate recognition for ubiquitin transfer, and the proteasome only performs the final act of protein degradation (Strehl et al., 2005; Ravid and Hochstrasser, 2008) . Seifert et al. show that interferon g upregulates expression of a series of E3 ligases and one E2 ligase UBE2C6 that appears to be required for efficient DRiP degradation. The authors also consider the ubiquitin-proteasome cycle in a broader context. The amount of free ubiquitin in cells is very small (5% of total ubiquitin) (Dantuma et al., 2006) . The rest is coupled to substrates as mono-or polyubiquitin, and the ubiquitin supply is largely obtained from ubiquitinated histones. Histone deubiquitination is observed within hours of proteasome inhibition, heat shock (Dantuma et al., 2006) , and interferon g treatment (Seifert et al., 2010) . Widespread histone deubiquitination should result in alterations in the transcriptome.
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How important is the dynamic exchange of standard proteasomes for immunoproteasomes in response to immunological stress? Seifert et al. test this by examining two mouse models of inflammation: inflammation induced by lipopolysaccharide (a component of the outer wall of Gram-negative bacteria) and experimental autoimmune encephalomyelitis (EAE; a demyelinating disorder often used as a model for multiple sclerosis). In these models, they observe elevated levels of oxidized proteins and polyubiquitin in liver and brain of immunoproteasome-deficient mice (that is, mice lacking lmp7/b5i). In addition, the inflammation induced by EAE is more severe in the absence of the immunoproteasome. These observations suggest that immunoproteasome induction during inflammation prevents harmful protein aggregation. Interestingly, the exchange of standard proteasome for immunoproteasomes is a slow process, and, prior to assembly of the immunoproteasome, DRiPs accumulate and form aggregates. At a later point in time, immunoproteasomes are able to dissolve and degrade the accumulated aggregates, which implies that the aggregates are dynamic, a possibility that warrants future study. Why immunoproteasomes are not always expressed to counter accumulation of DRiPs and other substrates is unclear. Possibly, constitutive immunoproteasome expression is deleterious in contexts other than the immune system. The fact that organisms such as yeast, flies, and nematodes only have one type of proteasome suggests that immunoproteasomes are an evolutionary adaption to particular conditions, such as the ones described by Seifert and colleagues.
The findings of Seifert and colleagues provide a new explanation for inflammation-induced tissue pathology. It also provides evidence that immunoproteasomes are important for the control of diseases induced by inflammation, including EAE. Further investigation will determine whether the dynamic exchange of proteasomes for immunoproteasomes fails under other conditions and how the immunoproteasome is involved in human pathologies.
Figure 1. Immunoproteasomes Prevent Protein Aggregate Formation
Exposure of cells to the inflammatory cytokine interferon induces a cascade of events including selective upregulation of major histocompatibility complex (MHC) class I, E3 and E2 UBE2C6 ubiquitin ligases, and immunoproteasome subunits b1i, b2i, and b5i. These assist in the handling of enhanced amounts of substrate that are the result of activation of the mTOR pathway. mTOR enhances translation, leading to the production of both nascent proteins and proteins that fail to form correctly, known as defective ribosomal products (DRiPs). Protein-damaging oxygen radicals are also formed upon interferon induction. Ubiquitin is present in limiting amounts for DRiP modification and is acquired from ubiquitin-modified histones. Deubiquitination of histones should affect the transcriptome. The normal proteasome cannot handle the enhanced pool of proteasome substrates, resulting in accumulated damaged protein aggregates and neuronal inflammatory diseases. The induced immunoproteasome has higher activity and is thus able to more efficiently degrade the substrate pool. Peptide fragments resulting from proteasome activity can serve in antigen presentation by MHC class I molecules.
